January 23, 2017
The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing the risks of acute generalized exanthematous pustulosis for Pfizer Japan’s psychoneurotic agent Atarax (hydroxyzine), and acute kidney injury for Chugai Pharmaceutical’s BRAF inhibitor Zelboraf (vemurafenib) - a move that is likely...read more